Hepatocellular carcinoma (HCC) is frequently diagnosed at late stages when curative treatments are no more applicable. Hence, it is essential to explore new strategie sagainst HCC. Long non-coding RNA (LncRNA) MAFG divergent transcript (MAFG-DT) was known to act as a modulator in various cancers. Nevertheless, the role of MAFG-DT in HCC remains unexplored. The Cancer Genome Atlas (TCGA) and bioinformatics analyzes were used to explore MAFG-DT level in HCC. In addition, LncBase was used to explore the downstream miRNA of MAFG-DT, and target scan was applied to analyze the targets of miR-339-5p. Meanwhile, bioinformatics tool was applied to assess the role of CDC25A and miR-339-5p in HCC. Furthermore, CCK8 and transwell assays were applied to assess the cell viability and migration. MAFG-DT level was elevated in HCC tissues. MAFG-DT level was positively correlated with the advanced TNM stage, vascular invasion, histologic grade recurrence and mortality. Kaplan–Meier analysis suggested that MAFG-DT was negatively associated with recurrence-free survival (RFS) and overall survival in HCC. Meanwhile, MAFG-DT was verified to sponge miR-339-5p, and CDC25A was the target mRNA of miR-339-5p. MAFG-DT silencing could significantly inhibit the viability of migration of HCC cells through binding to miR-339-5p. MAFG-DT silencing inhibited the development of HCC through miR-339-5p/CDC25A axis. Thus, our study might supply a new target against HCC.

在世界范围内,约有 3500 万人患阿尔茨海默病(AD) ,其发病率在未来 10 y 内预计还会增加,给公共卫生和医疗资源的分配带来巨大的挑战[ 1,2].目前治疗 AD 的药物主要包括胆碱酯酶抑制剂(例如多奈哌齐、 艾斯能、 加兰他敏) 以及NMDA 受体拮抗剂(例如美金刚) ,这些药物对 AD 的临床症状在短期内能发挥一定作用,但不能阻止疾病的进展.因此探索 AD 的替代治疗方法是必要的[ 3,4].脑深部刺激(Deep brain stinnlation,DBS) 是指利用立体定向手术,在脑内特定结构中植入电极,是一个复杂的神经调节过程[ 5].大量研究已经证实,脑深部刺激在运动障碍疾病的治疗中发挥重要的作用,如帕金森病[ 6]、 特发性震颤[ 7] 及肌张力障碍[ 8] 等.最近,脑深部刺激的应用已经开始扩展到神经精神疾病领域,如重度抑郁症[ 9]、 强迫症[ 10]、 抽动秽语综合征[ 11]、 神经性疼痛[ 12]及成瘾[ 13].癫痫也是 DBS 的重要适应证[ 14].基于 DBS 在神经系统疾病中的广泛应用,越来越多的研究开始探索 DBS对 AD 的治疗作用.

目的 探讨高频重复经颅磁刺激(HF rTMS)治疗抑郁症的短期增效作用及对认知功能的影响.方法 33例抑郁症患者在原有抗抑郁剂基础上接受2周10次rTMS,治疗前后采用汉密尔顿抑郁量表(HAMD-17)评定疗效,采用霍普金斯词语学习测试(HVLT-R)、 范畴流畅性动物命名(SVFA)、 韦氏记忆量表数字广度得分(WMS-DSS)评定认知功能.结果 治疗后2周的HAMD-17总分、HVLT-R、SVFA、WMS-DSS与治疗前相比,均有显著性差异(P<0.05).治疗后首发组HAMD总分明显下降,HVLT-R1、HVLT-R2、 粗分明显提高(P<0.05);复发组与治疗前相比,所有HVLT-R得分、SVFA均显著提高(P<0.01),WMS-DSS也明显升高(P<0.05).结论 HF rTMS对抑郁症有显著增效作用,并可不同程度改善患者的认知功能.

目的 探讨广东省某大型精神病专科医院的病人来源分布的规律与社会影响力,为医疗机构的健康发展、合理配置医疗资源提供科学依据.方法 利用医院病案管理系统,对住院患者病案首页的地址栏信息分析出院患者来源分布,研究医院服务范围的变化趋势.结果 在广州市脑科医院2010-2013年的19543例出院患者中,广州市住院病人数量呈逐年下降的趋势,而本省外市地区和外省病人数量持续上升趋势.结论 在大型精神专科医院的经营效果影响因素中,政策的支持、自身的医疗、教学、科研水平与医院的服务水平的提升与强烈的社会责任意识,对病源分布、社会影响力有深远的影响.

Objective To observe the clinical efficacy and security of oxycodone hydrochloride controlledrelease tablets combined with fluvoxamine in treating moderate and severe cancer pain complicated with depression.Methods One hundred and twenty patients with moderate and severe cancer pain complicated with depression from January 2013 to September 2014 were randomly divided into control group given oxycodone hydrochloride controlled-release tablets (titrating dosage) and observation group given oxycodone hydrochloride controlled-release tablets (titrating dosage) and fluvoxamine (first dose 50 mg/time,increased by 50-100 mg next day,≤300 rg/d).The pain numerical rating scale (NRS) score,self-rating depression scale (SDS) score,incidence of adverse reactions 4 weeks after treatment were compared between groups.Results After treatment,the NRS score and SDS score in observation group were significantly lower than those in control group [(1.5 ± 1.1) scores vs (2.1 ±1.1) scores,(42 t 7) scores vs (46 ± 8) scores] (P ＜ 0.05).The incidence of constipation in observation group was significantly lower than that in control group [31.7 ％ (19/60) vs 51.7 ％ (31/60)] (P ＜ 0.05),the incidences of other adverse effects were not significantly different between groups (P ＞ 0.05).Conclusion Fluvoxamine combined oxycodone hydrochloride controlled-release tablets can effectively control the cancer pain,relieve the symptom of depression,and reduce the adverse reactions induced by oxycodone hydrochloride controlled-release tahlets.

OBJECTIVE:to investigate the effect and side effects of recombinant human interleukin - 11 (rhIL - 11, in Chinese Juheli, produced by Qi Lu Biotechnology CO., LTD) in the second prevention of chemotherapy induced thrombocytopenia (CIT).METHODS:Cancer patients with CIT were recruited and were treated with rhIL - 11 (treatment phase, TP), and in the following cycle, all these patients administered with rhIL - 11 24 hours immediately after chemotherapy (preventive treatment phase, PTP). Duration and severity of thrombocytopenia between two phases were compared.RESULTS:for patients in TP or PTP, nadir values of platelet were (29.28±20.08)?109/L and (45.24±19.66)?109/L, duration of thrombocytopenia in TP and PTP was (11.52±4.33) and (8.20±+2.77)days, recovery time was (19.40±3.89)and (13.44±3.02)days, duration of rhIL - 11 administration was 10.68±2.46)and (6.28±1.77)days, number of patients needing platelet infusion was 16and4 respectively, all differences were statistically significant (p value were 0.007, 0.002, 0.000, 0.000, 0.034 respectively). For TP and PTP, number of patients with hemorrhage was 8 and 4, duration of bleeding was (5.00±0.82) and (4.50 ± 0.71) days respectively, with no statistically significant difference. Adverse reactions mainly included fever, edema, arrhythmia, joint pain, fatigue, skin rash, headache, dizziness, etc., all were not statistically significant between TP and PTP.CONCLUSION:rhIL - 11 could be well tolerated and is effective that could reduce the duration, severity of CIT, platelet transfusion, and incidence of bleeding, as well as shorten the recovery time, duration of rhIL - 11 administration. Thus, rhIL - 11 could be commended in the second prevention of CIT for patients with cancer.

目的：观察湿润烧伤膏( MEBO)治疗头面部皮肤挫裂伤的疗效。方法回顾分析头面部皮肤挫裂伤伤口清创缝合或者创面清创后,46例经传统外科处理的创面与52例规范应用MEBO换药皮肤再生疗法处理创面比较,观察疗效。结果52例规范应用MEBO换药皮肤再生疗法处理创面愈合天数为(7.5±1.1)d,均一期愈合。对照组愈合天数为(11.3±1.5)d。规范应用MEBO换药皮肤再生疗法处理创面患者的皮肤无明显增生性瘢痕、色素沉着数7例(13.46%)、止痛效果35(67.31%)、创面感染数3例(5.77%)均明显优于传统外科处理创面。结论 MEBO治疗急性头面部皮肤挫裂伤,疗效满意,方法简单易行。

目的:探讨导致颅内静脉窦血栓患者发生脑梗死的危险因素.方法:选取2011年10月至2015年8月期间我院收治的80例颅内静脉窦血栓患者作为研究对象.根据这80例患者发生脑梗死的情况将其分为脑梗死组(36例)和非脑梗死组(44例).笔者对两组患者的临床资料进行回顾性分析,从中找出导致颅内静脉窦血栓患者发生脑梗死的危险因素.结果:脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间平均为(55.22±28.02)天,非脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间平均为(20.22±8.19)天.与非脑梗死组患者相比,脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间更长,差异有统计学意义(P<0.05).在脑梗死组患者中,急性颅内静脉窦血栓患者有25例(占69.44%),亚急性颅内静脉窦血栓患者和慢性颅内静脉窦血栓患者共有11例(占30.56%).在非脑梗死组患者中,急性颅内静脉窦血栓患者有10例(占22.72%),亚急性颅内静脉窦血栓患者和慢性颅内静脉窦血栓患者共有34例(占77.28%).与非脑梗死组患者相比,脑梗死组患者中急性颅内静脉窦血栓患者的占比更高,差异有统计学意义(P<0.05).在脑梗死组患者中,上矢状窦处存在静脉血栓的患者有33例,横窦处存在静脉血栓的患者有32例.在非脑梗死组患者中,上矢状窦处存在静脉血栓的患者有26例,横窦处存在静脉血栓的患者有25例.与非脑梗死组患者相比,脑梗死组患者中上矢状窦处和横窦处存在静脉血栓的患者的人数更多,差异有统计学意义(P<0.05).结论:颅内静脉窦血栓患者出现静脉血栓至接受治疗的时间较长、其颅内静脉窦血栓为急性、其颅内静脉血栓分布于上矢状窦处和横窦处是导致其发生脑梗死的危险因素.临床医生应对上述情况予以关注.

Objective To analyze curative effect by thrombolytic therapy for secondary intracranial hemorrhage in intracranial venous sinus thrombosis.Methods A total of 13 patients with secondary intracranial hemorrhage in intracranial venous sinus thrombosis all received low molecular heparin anticoagulation combined with venous sinus local thrombolysis for treatment. Their curative effects were observed.Results Postoperative follow-up for 12 weeks showed 10 complete recovered cases, 2 cases with epilepsy sequela, and 1 rescue invalid death case due to cerebral hernia-induced respiratory and cardiac arrest.Conclusion Implement of local thrombolysis provides ideal effect in treating secondary intracranial hemorrhage in intracranial venous sinus thrombosis. This method is safe and creditable, and it can effective improve prognosis.

目的 建立人血清中色氨酸、犬尿氨酸、喹啉酸浓度测定的液相色谱串联质谱法.方法 以甲醇为提取剂,用蛋白沉淀法.色氨酸、犬尿氨酸以犬尿氨酸-13C4,15N为内标,色谱柱:Eclipse XDB-C18(4.6 mm×150 mm,5μm),流动相为甲醇-水(45∶55,均含5 mmol· L-1甲酸铵-0.1％甲酸);喹啉酸以喹啉酸-d3为内标,色谱柱:Eclipse plus C8柱(4.6 mm×100 mm,3.5 μm),流动相:甲醇-水(15∶85,0.75 mmol·L-1甲酸铵-0.4％甲酸);流速:0.5 mL·min-1,柱温:35℃;电喷雾离子源,以正离子多反应监测.考察该方法的专属性、标准曲线和定量下限、精密度与回收率、基质效应和稳定性.结果 色氨酸、犬尿氨酸、喹啉酸的线性范围分别为1000～3×104,100 ～ 3000,10～300 ng·mL-1;定量下限分别为1000,100,10 ng·mL-1;平均回收率均在80％以上,日内、日间精密度RSD均小于15％.结论 本方法操作简便,灵敏度高,分析快速,符合生物样品分析要求,适用于人血清中色氨酸及其代谢产物的浓度测定.

Objective To investigate the influence of icari n (ICA)on the expression of cyclooxygramse 2 (COX 2)in inflammational rat model hippocampus with Alzheimer’s disease(AD)induced by lipopolysaccharides(LPS). Methods Thirty six rats were al oca-ted into 4 groups:control group,model group,low dose ICA group and high dose ICA group.The rat models of AD were induced by being injected LPS into the lateral cerebral ventricle. After two weeks of intragastric administration,brain tissue of rats was removed. The expressions of COX 2 protein and mRNA in hippocampus of the rats were detected by immunohistochemistry(SP method)and SYBR GREEN fluorescence quantitative RT PCR. Results The expressions of COX 2 protein and mRNA in high dose ICA group were significantly lower than those in model group (P<0.01). Conclusion The high dose ICA can reduce the expression of COX 2 in inflammational rat model hippocampus of AD and can inhibit the inflammatory reaction of nerve cel s injury.

目的 考察犬尿氨酸活性物质在健康人与抑郁症患者血清中的含量差异,及抑郁症患者经rTMS治疗后犬尿氨酸活性物质含量变化趋势.方法 收集健康人(26例)及重复经颅磁刺激治疗前后抑郁症患者(54例)的血清;采用LC-MS/MS检测方法测定血清中色氨酸、犬尿氨酸和犬尿喹啉酸的含量.结果 抑郁症患者血清中色氨酸和犬尿氨酸浓度显著低于正常人,其差异有统计学意义(P＜0.002),但犬尿喹啉酸浓度差异无统计学意义(P＞0.05);抑郁症患者经rTMS治疗前后3种物质浓度差异无统计学意义(P＞0.05).结论 健康人与抑郁症患者血清中色氨酸和犬尿氨酸含量有差异,这两物质含量变化可能与抑郁症发病机制有关系.

目的 比较奥沙利铂联合替吉奥(SOX方案)和吉西他滨联合顺铂(GP方案)治疗晚期三阴性乳腺癌的疗效和不良反应.方法 晚期三阴性乳腺癌患者随机分别接受多周期SOX方案(SOX组,63例)和GP方案(GP组,57例)化疗.评价两组疗效和不良反应.结果 SOX组与GP组的总有效率(RR)分别为34.9％与35.1％,疾病控制率(DCR)为68.3％与70.2％,差异无统计学意义(P＞0.05);中位进展时间分别为9.5月与8.1月,差异有统计学意义(P=0.033);1年生存率分别为69.8％和63.2％,总生存时间(OS)分别为19.5月与18.7月,差异无统计学意义(P=0.554、0.207).常见的不良反应相似,其中腹泻、肝功能损害、外周神经毒性和手足综合征发生率SOX组明显高于GP组,血小板减少、恶心/呕吐、肾毒性和皮疹发生率GP组明显高于SOX组(P＜0.05).结论 奥沙利铂联合替吉奥、吉西他滨联合顺铂方案治疗晚期三阴性乳腺癌均安全、有效,不良反应耐受.

ObjectiveTo observe clinical effect by early application of alprostadil in the treatment of acute cerebral infarction.MethodsA total of 80 acute cerebral infarction patients were randomly divided into control group and experimental group, with 40 cases in each group. The control group received additional vinpocetine to conventional symptomatic treatment, and the experimental group received additional alprostadil instead. Curative effects were compared between the two groups.ResultsThe experimental group had higher total effective rate as 97.5% than 82.5% of the control group, and the difference had statistical significance (P<0.05). ConclusionEarly application of alprostadil shows remarkably clinical effect in treating acute cerebral infarction. This method is safe and creditable, and it contains clinical promoting and applying value.

Objective To evaluate the efficacy and toxicity of the combination of oxaliplatin and S-1 in the treatment of patients with advanced breast cancer.Methods A total of 72 patients with advanced breast cancer after the treatment failuer of anthracycline and taxane were treated with oxaliplatin and S-1.The first day,they were given oxaliplatin,135 mg/m2,with the 5％ glucose injection 500 ml,the time of intravenous drip should be more than 2 hours.And the S-1 was taken after breakfast and dinner,the dose was 40-60 mg,and the time of duration was 2 weeks,then they had 7 days to rest.The cycle was 21 days.Every 2 cycles,we estimated the efficacy.Patients who were effective and stable kept that chemotherapy regimens,the maximum duration was 6 cycles.The efficacy and toxicities were evaluated after cycles of chemotherapy.Results Two cases (2.8％) had complete response (CR),26 cases (36.1％) had partial response (PR).The response rate (RR) was 38.9％ and the disease control rate (DCR) was 69.4％.The median progress free survival (PFS) was 7.7 months and the median overall survival (OS) was 12.3 months.Subgroup analysis showed that the OS of patients who belong to stage Ⅳ,had two or more metastases or with failure treatment after being treated with anthracycline and taxane was notably shorter than the patients who belong to stage Ⅲ C,only one metastasis,with effective treatment after being treated with anthracycline and taxane,and the differences were statistically significant (10.5 months vs.15.0 months,x2 =4.469,P =0.035;9.3 months vs.15.0 months,x2 =8.297,P=0.004;10.0 months vs.14.0 months,x2 =4.077,P=0.043).The main side effects were neutropenia (19.4％),nausea (8.3％) and nerve toxicity (2.8％),mainly 3-4 degree,and could be welltolerated.The others were diarrhea,impaired liver function,stomatitis,anemia and hand-foot syndrome,mainly 1-2 degree.Conclusion Oxaliplatin combined with S-1 is effective and tolerable in treatment of patients with advanced breast cancer,the adverse reactions can be tolerated.

目的 探讨电子止吐仪干预改善吗啡缓释片所致恶心呕吐等消化系统不良反应的临床疗效.方法 选取癌痛程度为中重度的恶性肿瘤患者80例,随机分成对照组和观察组,每组40例,两组患者治疗前均无明显消化系统症状.对照组单独服用吗啡缓释片,观察组服用吗啡缓释片的同时持续使用电子止吐仪,比较治疗l周内两组患者在恶心、呕吐、便秘、卡氏功能状态(KPS)评分、疲劳、焦虑及食欲等方面的差异.结果 观察组和对照组第1～7天Ⅱ-Ⅳ度恶心呕吐的发生率分别为2.5％对7.5％、5.0％对20.0％、5.0％对22.5％、7.5％对25.0％、10.0％对27.5％、0.0％对7.5％及0.0％对5.0％,两组第2～5天各天恶心呕吐的发生率差异均具有统计学意义(P＜0.05);因恶心呕吐反应明显,对照组停药2例,观察组无停药病例.观察组和对照组的便秘发生率、KPS评分改善率、疲劳改善率、焦虑改善率及食欲改善率分别为67.5％和72.5％、57.5％和22.5％、52.5％和25.0％、62.5％和35.0％及52.5％和27.5％ (P＜0.05),除便秘发生率外,两组上述各项指标发生率组间差异均有统计学意义(P＜0.05).结论 电子止吐仪可显著改善吗啡缓释片所致恶心呕吐等不良反应,提高患者的生存质量,且未见新增其他严重不良反应.

Objective To observe clinical efficacy and safety on the treatment of moderate-severe cancer pain by Fluvoxamine combined with Oxycodone. Methods 120 cancer patients with moderate pain and 120 cases with severe pain were selected, randomly divided into experimental group and control group. The control group were given oxycodone alone , and experimental group given fluvoxamine combined with oxycodone , till the pain relieved, then the degree of pain relief, oxycodone dosage, life quality and side effects were evaluated. Results The degree of pain relief in experimental group were much better than control group (P < 0.05). Oxycodone consumption were lower in experimental group than control group , and the difference was no significant difference in controlling moderate pain (P = 0.065), while statistically significant in controlling severe pain (P = 0.035). The general status, daily activity, mood, and sleep affected by cancer pain were released after treatment, especially in experimental group (P < 0.05). The most common side effects were approximative, and the incidence of constipation, nausea/vomiting, lethargy were lower in experimental group than control group (P =0.026). Conclusion Fluvoxamine combined with Oxycodone can effectively control moderate-severe cancer pain, and reduce the oxycodone dosage and some side effects, and therefore, improve the quality of life.

目的 评价及探讨肝素钠结合静脉窦内机械破栓治疗静脉窦血栓的有效性及安全性.方法 从2014年10月至2014年12月对就诊于我科的3例难治性静脉窦血栓患者给予静脉泵入肝素抗凝,监测凝血时间,使其较正常值延迟1倍左右.继而行静脉窦内机械破栓治疗.3例患者均有静脉窦血栓形成的危险因素,术后积极控制原发病及去除病因,并给予持续抗凝6个月.结果 3例患者经肝素联合静脉窦内机械破栓治疗后,复查脑血管造影术静脉窦均再通,其腰椎穿刺查脑脊液压力明显下降,临床症状明显改善,无1例患者出现治疗并发症及症状复发.结论 肝素抗凝联合静脉窦内机械破栓治疗颅内静脉窦血栓形成安全有效的治疗手段.

Objective:To examine the effectiveness and safety of repetitive transcranial magnetic stimu-lation( rTMS)treatment on the right prefrontal cortex for patients in the manic episode of bipolar affective disor-der. Method:Thirty-three patients who met the criteria for bipolar disorder,manic episode in the diagnostic and statistical manual of mental disorders fourth edition were recruited. 17 of them were randomly chosen into the research group,and 16 into the control group. The dosage of sodium valproate for both groups was kept un-changed. Each subject in the research group received rTMS at 20 Hz,while the subjects in the control group re-ceived sham stimulation. Stimulation was once per day for 10 days. Before treatment,5 days into treatment,and 10 days into treatment,clinical effect were measured with the Bech-Rafaelsen mania rating scale( BRMS),and side effects were valuated with the treatment emergent symptom scale( TESS). Resuits:Before treatment and 5 days into treatment,there was no statistically significant difference in BRMS scores between the two groups (t=1. 439,t= -0. 204;P>0. 05). 10 days into treatment,the BRMS scores of the research group were signifi-cantly lower than those of the control group(t= -4. 558,P=0. 000). No obvious side effects were noticed. Conciusion:It is effective and safe to treat patients in the manic episode of bipolar disorder using rTMS on the right prefrontal cortex,combined with mood stabilizer.

目的：观察电子止吐仪联合盐酸帕洛诺司琼预防高致吐化疗药物所致急性胃肠道反应的疗效。方法将120例接受高致吐化疗药物治疗的患者随机分为2组：试验组60例应用电子止吐仪联合盐酸帕洛诺司琼，对照组60例应用帕洛诺司琼。观察和记录2组自化疗开始到化疗结束24 h内恶心、呕吐的发生情况。结果试验组和对照组呕吐反应完全控制率分别为40％，35％，2组大致相当（P＞0．05）；有效率分别为95．0％，78．3％，2组比较差异有统计学意义（P＜0．05）。试验组和对照组恶心反应在完全控制率分别为36．7％，30％，2组大致相当（P＞0．05）；有效率分别为90．0％，76．7％，2组比较差异有统计学意义（ P＜0．05）。结论电子止吐仪联合盐酸帕洛诺司琼预防高致吐化疗药物所致急性胃肠道反应优于单用盐酸帕洛诺司琼，可作为防治高致吐化疗药物所致急性期呕吐的常规措施。